Cyclacel Pharmaceuticals, Inc.
(NASDAQ : CYCC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.76%195.471.3%$555.99m
GILDGilead Sciences, Inc.
0.24%66.520.9%$368.70m
ALXNAlexion Pharmaceuticals, Inc.
-0.79%107.402.0%$321.44m
ILMNIllumina, Inc.
1.14%300.913.5%$301.00m
BIIBBiogen Inc.
1.86%236.631.3%$288.49m
CELGCelgene Corporation
-0.23%98.401.3%$282.90m
AAgilent Technologies, Inc.
0.43%77.901.6%$193.04m
SRPTSarepta Therapeutics, Inc.
-2.25%86.0014.7%$180.31m
VRTXVertex Pharmaceuticals Incorporated
1.44%174.941.9%$173.66m
REGNRegeneron Pharmaceuticals, Inc.
-0.90%281.622.6%$171.53m
EXASExact Sciences Corporation
-1.82%106.7124.1%$132.03m
ACADACADIA Pharmaceuticals Inc.
3.35%40.4513.9%$98.63m
INCYIncyte Corporation
0.47%76.432.5%$83.43m
BMRNBioMarin Pharmaceutical Inc.
-0.21%72.654.3%$76.16m
IONSIonis Pharmaceuticals, Inc.
-1.02%66.208.2%$63.42m

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.